Literature DB >> 23760051

Systemic protein therapy for recessive dystrophic epidermolysis bullosa: how far are we from clinical translation?

Alain Hovnanian1.   

Abstract

In this issue, Woodley et al. report restoration of anchoring fibril formation and dermal-epidermal adherence in a murine model of recessive dystrophic epidermolysis bullosa (RDEB) by intravenous injection of recombinant human type VII collagen. This work follows a previous report by the same group of the surprising capability of intradermally injected type VII collagen protein to reverse RDEB, and it opens new therapeutic avenues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760051     DOI: 10.1038/jid.2013.137

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

Review 1.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 2.  Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects.

Authors:  I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov
Journal:  Bull Exp Biol Med       Date:  2021-05-29       Impact factor: 0.804

Review 3.  Dystrophic epidermolysis bullosa: a review.

Authors:  Satoru Shinkuma
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-26

4.  A case of a patient with severe epidermolysis bullosa surviving to adulthood.

Authors:  Amal R Hubail; Roza K Belkharoeva; Natalya P Tepluk; Olga V Grabovskaya
Journal:  Int J Gen Med       Date:  2018-11-15

5.  Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model.

Authors:  Yanling Liao; Larisa Ivanova; Rajarajeswari Sivalenka; Trevor Plumer; Hongwen Zhu; Xiaokui Zhang; Angela M Christiano; John A McGrath; Jodi P Gurney; Mitchell S Cairo
Journal:  Stem Cells Transl Med       Date:  2018-05-10       Impact factor: 6.940

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.